Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

943
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Lp(a) as Driver for Lipid Lowering Strategy Optimization in Patients at High and Very-high Risk: beyond LDL-C.

The American journal of cardiology·2026
Same author

Assessment of Peripheral Arterial (Normal) Flows in Multiple Vascular Territories in Patients Receiving Mechanical Cardiac Support.

Journal of cardiovascular echography·2026
Same author

Mechanical load inhibits cancer growth in mouse and human hearts.

Science (New York, N.Y.)·2026
Same author

Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

Diffuse Cutaneous Systemic Sclerosis Complicated by Serum Amyloid A Protein Cardiac Amyloidosis and Cardiogenic Shock.

CJC open·2026
Same author

Prognostic value of right ventricle-pulmonary artery coupling in intensive cardiac care unit.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026

相关实验视频

Updated: May 5, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

16.3K

组织因子通路抑制剂在急性冠状动脉综合征患者的冠状动脉循环中的参与

Paolo Golino1, Amelia Ravera, Massimo Ragni

  • 1Department of Internal Medicine and Cardiovascular Sciences, Division of Cardiology, University of Naples Federico II, Naples, Italy. paolo.golino@unina2.it

Circulation
|December 6, 2003
PubMed
概括

组织因子通路抑制剂 (TFPI) 在急性冠状动脉综合征 (ACS) 患者中较低,表明其参与血栓形成. 这表明TFPI可能在调节冠状动脉血栓形成方面发挥作用.

更多相关视频

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.4K
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

1.8K

相关实验视频

Last Updated: May 5, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

16.3K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.4K
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

1.8K

科学领域:

  • 心血管医学 心血管医学
  • 血液学 血液学 血液学
  • 血栓形成的研究研究

背景情况:

  • 组织因子通路抑制剂 (TFPI) 是外部凝固级联的主要内源性抑制剂.
  • 在急性冠状动脉综合征 (ACS) 中,TFPI在血栓形成过程中的特定作用仍然在很大程度上未被描述.

研究的目的:

  • 在活体中调查TFPI在ACS患者的血栓形成过程中的参与.
  • 为了比较ACS患者的TFPI水平与接受皮肤冠状动脉干预 (PCI) 的稳定性心痛.

主要方法:

  • 在血中测量跨心脏 (大动脉/冠状动脉鼻) 自由和总TFPI,TFPI/XA因子 (FXa) 复合物的水平.
  • 分析急性心肌梗塞 (AMI) 或接受初级/紧急PCI的不稳定性心痛患者和接受选择性PCI的稳定性心痛患者的血样本.
  • 在基线,PCI后和支架部署后评估1+2和纤维蛋白A水平.

主要成果:

  • 在ACS患者中,冠状动脉鼻水平的总和自由TFPI都明显低于大动脉水平.
  • 与大动脉相比,ACS患者在冠状动脉鼻中表现出明显增加的TFPI/FXa复合物水平.
  • 稳定性胸痛患者在TFPI或TFPI/FXa水平在冠状动脉鼻和大动脉之间没有显著差异.

结论:

  • 在ACS患者的冠状动脉血管内,TFPI活跃参与体内血栓形成.
  • 这些发现表明TFPI在调节ACS中的冠状动脉血栓形成方面的潜在治疗作用.